# Powder supplement brand AG1 is exploring a sale option involving the whole company.

*business · news · 2026-04-11 · Devdiscourse*

## Key points

- C4 Therapeutics and Roche signed a $1 billion deal for degrader-antibody conjugate cancer drugs.
- The C4-Roche partnership targets undisclosed oncology indications under exclusive agreement terms.
- AG1, also known as Athletic Greens, is considering a full or partial sale valued over $2 billion.
- Granules India will digitize documentation and tighten oversight after an FDA warning for manufacturing violations.

**Companies:** Roche, C4 Therapeutics, Goldman Sachs, Granules India
**Countries:** United States, India

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3870173-health-sector-shifts-cancer-deals-supplement-sales-and-drug-approvals)

---

Canonical: https://newsio.io/n/bdc19ec6-e9ea-4d58-986b-68754e0f32fc/powder-supplement-brand-ag1-is-exploring-a-sale-option-involving-the-whole-compa
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works